Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent

NCT01303692 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01303692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01303692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
April 30, 2011
Completion date
February 28, 2014
Enrollment
312 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gnrh agonist alone vs. gnrh agonist plus anti-androgen combination treated prostate cancer patients